publication . Article . Other literature type . 2015

Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS

Caspar, Achim T.; Helfer, Andreas G.; Michely, Julian A.; Auwärter, Volker; Brandt, Simon D.; Meyer, Markus R.; Maurer, Hans H.;
Open Access English
  • Published: 25 Jun 2015
  • Publisher: SPRINGER HEIDELBERG
  • Country: United Kingdom
Abstract
25I-NBOMe, a new psychoactive substance, is a potent 5-HT2A receptor agonist with strong hallucinogenic potential. Recently, it was involved in several fatal and non-fatal intoxication cases. The aim of the present work was to study its phase I and II metabolism and its detectability in urine screening approaches. After application of 25I-NBOMe to male Wistar rats, urine was collected over 24 h. The phase I and II metabolites were identified by LC-HR-MS/MS in urine after suitable workup. For the detectability studies, standard urine screening approaches (SUSA) by GC-MS, LC-MSn, and LC-HR-MS/MS were applied to rat and also to authentic human urine samples submitt...
Subjects
free text keywords: RM, RS, Analytical Chemistry, Biochemistry, Designer drug, medicine.drug_class, medicine, Chemistry, Glucuronidation, CYP1A2, Sulfation, Urine, 25I-NBOMe, medicine.drug, Pharmacology, CYP3A4, Hydroxylation, chemistry.chemical_compound
Related Organizations

1. Maurer HH (2010) Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse [review]. Ther Drug Monit 32:544-549 2. Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Brauner-Osborne H, 27. Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of MS1 MS2 MS1 MS2 MS1 MS2 MS1 MS2 MS1 MS2 MS1 MS2 MS1 MS2 MS1 MS2 MS1 MS2

Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue